Le Lézard
Classified in: Ebola virus, Health
Subject: ACC

Zinzino AB (publ.) cancels warrants that have not been exercised


GOTHENBURG, Sweden, May 2, 2023 /PRNewswire/ -- Zinzino AB (publ.) announces that the company has started the process of canceling all 800,000 warrants in the 2021-01 series with an exercise price of SEK 140 and which expires on 2026-05-31. No warrants in the series have been subscribed to date, whereby the board wishes to create space for the upcoming annual general meeting of the company to decide on new, more attractive incentive programs for key personnel in the external distributor organization and for senior executives in the group.

The scrapping means that the maximum dilution, if all warrants held by warrant holders in the other currently issued warrant programs are exercised and new shares are subscribed, is reduced from approximately 9.2 percent to 6.8 percent of the total number of outstanding shares. For more information on current outstanding option programs, please visit www.zinzino.com for more information.

For more information please contact:

Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, email: [email protected]

Fredrik Nielsen CFO Zinzino +46 707 900 174, email: [email protected]

Images for free publication:
[email protected]

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: [email protected]

 

The following files are available for download:

https://mb.cision.com/Main/10976/3761120/2022797.pdf

Pressrelease Cancellation of warrants that have not been exercised

 


These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: